Clinical trial NCT05134857: The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
Official title: Zonisamide for the Treatment of Alcohol Use Disorder in the Addiction Neuroclinical Assessment Framework
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Alcohol Use Disorder (AUD)
Keywords: Alcohol Use Disorder
Zonisamide
Contingency Management
Incentives for Sobriety
Lead sponsor: Washington State University
Sponsor class: OTHER
First posted: 2021-11-26
Enrollment: 205
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A phase II randomized, double-blind, placebo-controlled clinical trial
Primary purpose: TREATMENT

Brief summary: A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).

Detailed description: This project focuses on the efficacy of a promising pharmacotherapy (ZON) for AUDs using a placebo-controlled design that will rigorously measure alcohol use and medication adherence. Results will guide novel mechanistic targets to better capture the heterogeneity within AUDs. This project will evaluate the ability of ZON to treat the alcohol use disorder.

The investigators hypothesize that the group assigned to ZON associated with the standard treatment (ZON+ST) will yield lower rates of biochemically verified alcohol use, fewer self-reported drinks per day, and fewer heavy drinking days during the 12-week treatment and 1-year follow-up periods, relative to the placebo associated with the standard treatment (PLO+ST) group.

Eligibility criteria: Inclusion Criteria:

1. Four or more standard drinks on four or more occasions in the prior 30 days.
2. Seeking AUD treatment.
3. Aged 18-65 years.
4. DSM-5 diagnosis of AUD.
5. Ability to read and speak English.
6. Ability to provide written informed consent.
7. Breath alcohol of 0.00 during informed consent.
8. Provision of at least 1 EtG-positive urine test at any time during the induction period.
9. Non-lactating women of childbearing age using reliable form of birth control with a negative urine pregnancy test at baseline, and
10. Attended at least 4 of 6 visits during the induction period.

Exclusion Criteria:

1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal;
2. Currently receiving any pharmacotherapy for alcohol or in the past 30 days.
3. Current DSM-5 diagnosis of severe substance use disorder other than nicotine.
4. Suicide attempt in the last 20 years.
5. History of hypersensitivity to sulfonamide medication, Stevens-Johnson Syndrome, penicillin allergy or allergic reaction to any drug
6. Systemic autoimmune disease.
7. History of current seizure disorder (e.g., are they receiving medication currently for their seizures, have they ever been told by their provider that they have epilepsy, or do they have a history of recurring seizures in the last 5 years?).
8. Current clinically significant blood dyscrasia.
9. History of clinically significant renal calculi or renal failure; renal compromise (defined by an elevation of serum creatinine above our laboratory's limit of normal).
10. History of traumatic brain injury (TBI; e.g., ever been told by a provider that they had a moderate or severe TBI, lost consciousness for 30 minutes or longer or had a post-traumatic amnesia lasting a day or longer).
11. Any other current, clinically significant physical disease \[i.e., neurologic, renal, rheumatologic, gastrointestinal, hematologic, pulmonary, endocrine, cardiovascular, hepatic, or autoimmune disease\] on the basis of medical history, physical examination, or routine laboratory evaluation that, in the context of the study would represent a risk to the subject, or significant laboratory abnormalities related to hepatic function such as marked elevations of hepatic aminotransferase levels (i.e., AST and ALT) or direct bilirubin, and
12. Any other medical or psychiatric condition that Dr. Rodin determines would compromise safe participation.

Primary outcomes:
measure: Change in Self Reported Alcohol Consumption
timeFrame: 12-week treatment and 1-year follow-up period
Secondary outcomes:
measure: Change in Biochemically Verified Alcohol Consumption
timeFrame: 12-week treatment and 1-year follow-up period
Other outcomes:
measure: Adverse Events
timeFrame: 12-week treatment and 1-year follow-up period
Locations:
city: Spokane
country: United States
facility: Washington State University
state: Washington
Study officials:
References: